Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramy Badawi

Cardiovascular Disease Kailua, HI Medical Doctor

NPI 1326238510 CMS profile 828130

640 Ulukahiki St, Kailua, HI 96734

Open in the dashboard

General payments

$77,756

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramy Badawi of Kailua, HI is reported in the CMS Open Payments database as having received $77,756 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,792 44
2024 General $15,949 57
2023 General $7,643 36
2022 General $7,648 37
2021 General $14,581 44
2020 General $18,769 28
2019 General $8,375 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramy Badawi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ramy Badawi were reported at $4,792. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ramy Badawi Cardiovascular Disease median Middle half National median
2019 $8,375 $450 $127–$1,392 $163
2020 $18,769 $242 $77–$751 $114
2021 $14,581 $335 $101–$1,037 $132
2022 $7,648 $395 $121–$1,211 $149
2023 $7,643 $443 $136–$1,283 $160
2024 $15,949 $450 $136–$1,323 $164
2025 $4,792 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $32,043 91 payments
  2. Boston Scientific Corporation $23,923 38 payments
  3. Shockwave Medical, Inc $8,607 54 payments
  4. Abbott Laboratories $3,228 22 payments
  5. Philips Electronics North America Corporation $2,311 9 payments
  6. Baylis Medical Company Inc $2,246 8 payments
  7. Penumbra, Inc. $1,658 14 payments
  8. Teleflex LLC $1,233 10 payments
  9. Biotronik Inc. $622 6 payments
  10. Inari Medical, Inc. $423 2 payments
  11. Other $1,462 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $25,850 7 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,101 6 payments
  3. Food and Beverage $18,758 250 payments
  4. Travel and Lodging $8,687 20 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,300 3 payments
  6. Education $60 1 payment
Products named General payments · program years 2019–2025
  1. Impella $31,567 80 payments
  2. General - Therapies $12,760 3 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $5,903 25 payments
  4. GENERAL - VASCULAR ACCESS $4,800 1 payment
  5. CROSSBOSS $4,500 1 payment
  6. Coronary Other $2,311 9 payments
  7. VersaCross Access Solution $2,246 8 payments
  8. DRAGONFLY OPSTAR $2,246 9 payments
  9. Vascular Lithotripsy $1,102 10 payments
  10. Indigo System $825 9 payments
  11. Other $9,490 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

60

Median for Interventional Cardiology: 2,236

Drug cost

$11,924

Median for Interventional Cardiology: $380,412

Branded share of claims

100%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 22 $11,511
Clopidogrel Clopidogrel Bisulfate Brand 38 $413

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$60,942

Medicare's payments for the services billed

Medicare patients

78

Average age 73

Services billed

420

23 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 62%
Chronic kidney disease 59%
Diabetes 56%
Atrial fibrillation 38%
Arthritis 33%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record